Capital Com MENA Securities Trading LLC is regulated by the Capital Market Authority.
Open platformOpen platform

Moderna's mNEXSPIKE shows 35.9% relative effectiveness against medically attended COVID-19 versus Comirnaty in older adults

By Public Technologies
  • Moderna announced published results in JAMA Network Open comparing its mNEXSPIKE COVID-19 vaccine with Comirnaty.
  • The real-world study included 294,499 matched US veterans aged 65 and older during the 2025-2026 respiratory virus season.
  • mNEXSPIKE was associated with fewer COVID-19 hospitalizations and medically attended cases than Comirnaty.
  • An exploratory analysis also linked mNEXSPIKE to fewer hospitalizations involving major adverse cardiovascular events.
  • The observational findings do not establish causality; the predominantly older, male population may limit applicability to broader populations.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202611111110ACCESSWRNAPR_____1249376) on November 11, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.